[1] 総務省統計局、統計トピックス No. 126 (令和 2 年 9 月 20 日) https://www.stat.go.jp/data/topics/topi1260.html
[2] 厚生労働省、令和元年社会医療診療行為別統計の概況. (2019)
[3] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M. Sarcopenia: European consensus on definition and diagnosis. Age and Ageing. 39 (4), 412-423 (2010)
[4] Yamada M, Nishiguchi S, Fukutani N, Tanigawa T, Yukutake T, Kayama H, Aoyama T, Arai H. Prevalence of Sarcopenia in community-dwelling Japanese older adults. J Am Med Dir Assoc. 14 (12), 911-915 (2013)
[5] Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 16 (1), 31-41 (1976)
[6] Drusano GL, Muncie HL, Hoopes JM, Damron DJ, Warren JW. Commonly used methods of estimating creatinine clearance are inadequate for elderly debilitated nursing home patients. J Am Geriatr Soc. 36 (5), 437-441 (1988)
[7] Dowling TC, Wang ES, Ferrucci L, Sorkin JD. Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the baltimore longitudinal study on aging (BLSA): Impact on renal drug dosing. Pharmacotherapy. 33 (9), 912-921 (2013)
[8] Gunnarsson SI, · Palsson R, Sigurdsson G, Indridason OS. Relationship between Body Composition and Glomerular Filtration Rate Estimates in the General Population. Nephron Clin Pract. 123 (1-2), 22-27 (2013)
[9] Bretagne M, Jouinot A, Durand JP, Tlemsani C, Arrondeau J, Huillard O, Boudou RP, Goldwasser F, Alexandre J. Estimation of glomerular filtration rate in patients with abnormal body composition and relation with carboplatin toxicity. Ann. Oncol. 27 (1), 45–53 (2016)
[10] Donadio C. Body Composition Analysis Allows the Prediction of Urinary Creatinine Excretion and of Renal Function in Chronic Kidney Disease Patients. Nutrients. 9 (6) 533 (2017)
[11] Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 352 (21), 2211-2221 (2005)
[12] Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 76 (3), 391-396 (2007)
[13] Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 64 (12), 1147-1161 (2008)
[14] Periáñez-párraga L, Martínez-lópez I, Ventayol-bosch P, Puigventós-latorre F, Delgado-sánchez O. Drug dosage recommendations in patients with chronic liver disease. Rev Esp Enferm Dig. 104 (4), 165-184 (2012)
[15] Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N- acetyltransferase-2, and xanthine oxidase with the 'Cooperstown cocktail'. Clin Pharmacol Ther. 68 (4), 375-383 (2000)
[16] Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba ADM, Rowland E, Bertino JS. Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther. 74 (5), 437-447 (2003)
[17] Christensen M, Andersson K, Dalén P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G, Wahlberg A, Yaşar Ü, Bertilsson L. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther. 73 (6), 517-528 (2003)
[18] Ryu JY, Song IS, Sunwoo YE, Shon JH, Liu KH, Cha IJ, Shin JG. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin Pharmacol Ther. 82 (5), 531-540 (2007)
[19] Won HJ, Chung G, Lee KJ, Lee E, Son S, Choi S, Park SC, Lee YJ. Evaluation of medication dosing errors in elderly patients with renal impairment. Int. Journal of Clinical Pharmacology and Therapeutics. 56 (08), 358-365 (2018)
[20] Chung SM, Lee DJ, Hand A, Young P, Vaidyanathan J, Sahajwalla C. Kidney function changes with aging in adults: comparison between cross-sectional and longitudinal data analyses in renal function assessment. Biopharm Drug Dispos. 36 (9), 613-621 (2015)
[21] Kumar BV, Mohan T. Retrospective Comparison of Estimated GFR using 2006 MDRD, 2009 CKD- EPI and Cockcroft-Gault with 24 Hour Urine Creatinine Clearance. J Clin Diagn Res. 5 (11), BC09- BC12 (2017)
[22] Aizawa M, Hayashi K, Shimaoka T, Yamaji K, Horikoshi S, Tomino Y. Comparison of prediction equations of glomerular filtration rate of Japanese adults. Jpn J Nephrol. 48 (2), 62-66 (2006)
[23] Chaverri-Ferandez JM, Zavaleta-Monestel E, Diaz-Madriz JP, Ortiz-Urena A, Ramirez-Hernandez M, Trejos-Morales K. Analysis of the concordance between the estimated values of creatinine clearance using the Cockcroft-Gault equation and the real value determined in patients from the Hospital Clinica Biblica. Farm Hosp. 40 (1), 3-13 (2010)
[24] Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol. 5 (6), 1003-1009 (2010)
[25] Stevens LA, Nolin TD, Richardson MM, Feldman HI, Lewis JB, Rodby R, Townsend R, Okparavero A, Zhang Y, Schmid CH, Levey AS. Comparison of Drug Dosing Recommendations Based on Measured GFR and Kidney Function Estimation Equations. Am J Kidney Dis. 54 (1), 33-42 (2009)
[26] Horio M, Orita Y, Manabe S, Sakata M, Fukunaga M. Formula and nomogram for predicting creatinine clearance from serum creatinine concentration. Clin Exp Nephrol. 1 (2), 110-114 (1997)
[27] Levey AS, Bosch JP, Lewis JB, Greece T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 130 (6), 461-470 (1999)
[28] Terawaki H, Nakayama M, Asahi K, Kakamu T, Hayakawa T, Iseki K, Kimura K, Moriyama T, Yamagata K, Narita I, Fujimoto S, Tsuruya K, Konta T, Kondo M, Kurahashi I, Ohashi Y, Fukushima T, Watanabe T. Comparison of predictive value for first cardiovascular event between Japanese GFR equation and coefficient-modified CKD-EPI equation. Clin Exp Nephrol. 19 (3), 387-394 (2015)
[29] Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised Equations for estimating glomerular filtration rate (GFR) from serum creatinine in Japan. Am J Kidney Dis. 53 (6), 982-992 (2009)
[30] World Health Organization. Body mass index (BMI). https://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy- lifestyle/body-mass-index-bmi
[31] Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 5, 303-311-313 (1989)
[32] Echizen H. Yakubutsu touyo keikaku manual. (in Japanese) IGAKU-SHOIN Japan, pp21-23. (1986)
[33] Kanno T. Wakaru Rinsyou yakubutsudoutai Riron no Ouyou. (in Japanese) Iyaku (Medicine and Drag) Journal Co., Ltd. Japan, pp45-47. (1998)
[34] Horio M, Orita Y. Comparison of Jaffe rate assay and enzymic method for the measurement of creatinine clearance. Jpn J Nephrol. 38 (7), 296-299 (1996)
[35] Toda T, Watanabe H, Kurosawa N, Owada E, Achiwa K, Yuhki Y, Tadano K, Takahashi Y, Harada H, Seki T, Harada T. Limited sampling strategy for estimating area under the concentration curve for mycophenolic acid in renal transplant recipients with Co-administration of Tacrolimus. Jpn J Pharm Health Care Sci. 30 (1), 1-7 (2004)
[36] 厚生労働省、患者調査の概況. (2014) http://www.mhlw.go.jp/toukei/saikin/hw/kanja/14/dl/01.pdf
[37] Riccobene T, Jakate A, Rank D. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end- stage renal disease requiring hemodialysis. J Clin Pharmacol. 54 (7), 742-752 (2014)
[38] Japanese Society of Nephrology. Clinical Practice Guidebook for diagnosis and Treatment of Chronic Kidney Disease 2012. Nephrol Dial Transplant. 32, 798-806 (2012).
[39] Pottel H, Hoste L, Dubourg L, Ebert N, Schaeffner E, Eriksen BO, Melsom T, Lamb EJ, Rule AD, Turner ST, Glassock RJ, De Souza V, Selistre L, Mariat C, Martens F, Delanaye P. An estimated glomerular filtration rate equation for the full age spectrum. Nephrol Dial Transplant. 31 (5), 798- 806 (2016)
[40] Ebah LM, Wiig H, Dawidowska I, O'Toole C, Summers A, Nikam M, Jayanti A, Coupes B, Brenchley P, Mitra S. Subcutaneous interstitial pressure and volume characteristics in renal impairment associated with edema. Kidney Int. 84 (5), 980-988 (2013)
[41] Bouquegneau A, Vidal-Petiot E, Moranne O, Mariat C, Boffa JJ, Vrtovsnik F, Scheen AJ, Krzesinski JM, Flamant M, Delanaye P. Creatinine-based equations for the adjustment of drug dosage in an obese population. Br J Clin Pharmacol. 81 (2), 349-361 (2015)
[42] Helou R. Should We Continue to Use the Cockcroft-Gault Formula? Nephron Clin Pract. 116, 172- 186 (2010)
[43] Westhuyzen J. Cystatin C: a promising marker and predictor of impaired renal function. Ann Clin Lab Sci. 36(4), 387-94 (2006)
[44] Kaburaki S, Yoshimura E, Kojima N, Ueno H, Sugawara M, Takekuma Y. Improvement of renal function estimation equations for elderly Japanese people. Health Sci Rep. e85 (2018)
[45] Fanali G, Di MA, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: From bench to bedside. Mol. Aspects Med. 33 (3), 209-290 (2012)
[46] Ida S, Kaneko R, Imataka K, Murata K. Association between Sarcopenia and Renal Function in Patients with Diabetes: A Systematic Review and Meta-Analysis. J Diabetes Res. 1365189 (2019)
[47] Cabrerizo S, Cuadras D, Gomez-Busto F, Artaza-Artabe I, Marín-Ciancas F, Malafarina V. Serum albumin and health in older people: Review and meta analysis. Maturitas. 81(1), 17-27 (2015)
[48] Ozmen S, Kaplan MA, Kaya H, Akin D, Danis R, Kizilkan B, Yazanel O. Role of lean body mass for estimation of glomerular filtration rate in patients with chronic kidney disease with various body mass indices. Scand J Urol Nephrol. 43(2), 171-176 (2009)
[49] Chew-Harris JS, Florkowski CM, Elmslie JL, Livesey J, Endre ZH, George PM. Lean mass modulates glomerular filtration rate in males of normal and extreme body composition. Intern Med J. 44(8), 749-756 (2014)
[50] Chen YY, Fang WH, Wang CC, Kao TW, Chang YW, Yang HF, Wu CJ, Sun YS, Chen WL. Changes of Percent Body Fat as a Useful Surrogate for Risk of Declined Renal Function. Sci Rep. 23;8(1), 17289 (2018)
[51] Narici MV, Maffulli N. Sarcopenia: characteristics, mechanisms and functional significance. Br Med Bull. 95, 139-59 (2010)
[52] Tai R, Ohashi Y, Mizuiri S, Aikawa A, Sakai K. Association between ratio of measured extracellular volume to expected body fluid volume and renal outcomes in patients with chronic kidney disease: a retrospective single-center cohort study. BMC Nephrol. 15:189 (2014)
[53] Dutra MT, Avelar BP, Souza VC, Bottaro M, Oliveira RJ, Nóbrega OT, Moreno Lima R. Relationship between sarcopenic obesity-related phenotypes and inflammatory markers in postmenopausal women. Clin Physiol Funct Imaging. 37(2), 205-210 (2017)
[54] Sipilä, S. Body composition and muscle performance during menopause and hormone replacement therapy. J Endocrinol Invest 26, 893–901 (2003)
[55] Nakatani S, Maeda K, Akagi J, Ichigi M, Murakami M, Harada Y, Utsumi S, Fukunaga M, Narita Y, Kondo Y, Ishitsuka Y, Irie T, Kadowaki D, Hirata S. Coefficient of Determination between Estimated and Measured Renal Function in Japanese Patients with Sarcopenia May Be Improved by Adjusting for Muscle Mass and Sex: A Prospective Study. Biol Pharm Bull. 42(8), 1350-1357 (2019)
[56] Chisaki Y, Aoji S, Yano Y. Analysis of adverse drug reaction risk in elderly patients using the Japanese adverse drug event report (JADER) database. Biol Pharm Bull. 40 (6), 824-829 (2017)
[57] Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 63 (2), 187-195 (2006)
[58] Davies EA, O'Mahony MS. Adverse drug reactions in special populations - the elderly. Br J Clin Pharmacol. 80 (4), 796-807 (2015)
[59] Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 57 (1), 6-14 (2003)
[60] Ribeiro SML, Kehayias JJ. Sarcopenia and the Analysis of Body Composition. Adv Nutr. 5 (3), 260- 267 (2014)
[61] Munhoz da Rocha Lemos Costa T, Costa FM, Jonasson TH, Moreira CA, Boguszewski CL, Borba VZC. Body composition and sarcopenia in patients with chronic obstructive pulmonary disease. Endocrine. 60(1), 95-102 (2018)
[62] Gurley BJ, Gardner SF, Hubbard MA, Keith Williams D, Brooks Gentry W, Cui Y, Ang CYW. Clinical assessment of botanical supplementation on cytochrome P450 phenotypes in the elderly: St. John's Wort, Garlic oil, Panax ginseng and Ginkgo biloba. Drugs and Aging. 22 (6), 525-539 (2005)
[63] Wei YL, Du HJ, Lin YP, Wu ML, Xu RA. Effects of salidroside on rat CYP enzymes by a cocktail of probe drugs. Iran J Basic Med Sci. 21 (4), 422-426 (2018)
[64] Fukuoka Y, Narita T, Fujita H, Morii T, Sato T, Sassa M Harada, Yamada Y. Importance of physical evaluation using skeletal muscle mass index and body fat percentage to prevent sarcopenia in elderly Japanese diabetes patients. J Diabetes Investig. 10 (2), 322-330 (2019)
[65] Hamaguchi Y, Kaido T, Okumura S, Kobayashi A, Shirai H, Yagi S, Kamo N, Okajima H, Uemoto S. Impact of skeletal muscle mass index, intramuscular adipose tissue content, and visceral to subcutaneous adipose tissue area ratio on early mortality of living donor liver transplantation. Transplantation. 101 (3), 565-574 (2017)
[66] Yuki A, Ando F, Otsuka R, Shimokata H. Sarcopenia based on the Asian Working Cohort for Sarcopenia criteria and all-cause mortality risk in older Japanese adults. Geriatr Gerontol Int. 17 (10), 1642-1647 (2017)
[67] Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, Chou MY, Chen LY, Hsu PS, Krairit O, Lee Jenny S.W., Lee WJ, Lee Y, Liang CK, Limpawattana P, Lin CS, Peng LN, Satake S, Suzuki T Won CW, Wu CH, Wu SN, Zhang T, Zeng P, Akishita M, Arai H. Sarcopenia in Asia: Consensus Report of the Asian Working Cohort for Sarcopenia. J Am Med Dir Assoc. 15 (2), 95- 101 (2014)
[68] Kim B, Ahn SH, Lee SH, Hong S, Hamrick MW, Isales CM, Koh J. Lower hand grip strength in older adults with non-alcoholic fatty liver disease: a nationwide population-based study. Aging. 11 (13), 4547-4560 (2019)
[69] Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Kim YJ, Yoon JH, Cho SH, Sung MW, Lee HS. Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 42 (7), 503-508 (2010)
[70] Song M, Gao X, Hang T, Wen A. Simultaneous determination of lansoprazole and its metabolites 5′-hydroxy lansoprazole and lansoprazole sulphone in human plasma by LC-MS/MS: Application to a pharmacokinetic study in healthy volunteers. J Pharm Biomed Anal. 48 (4), 1181- 1186 (2008)
[71] Wang X-D, Li J-L, Lu Y, Chen X, Huang M, Chowbay B, Zhou S-F. Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography– tandem mass spectrometry: Application to a clinical herb–drug interaction study. J Chromatogr B. 852 (1-2), 534-544 (2007)
[72] Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol. 199(3): 193-209 (2004)
[73] Baumgartner RN. Body Composition in Healthy Aging. Ann NY Acad Sci. 904 (1), 437-448 (2006)
[74] Kera T, Kawai H, Hirano H, Kojima M, Fujiwara Y, Ihara K, Obuchi S. Differences in body composition and physical function related to pure sarcopenia and sarcopenic obesity: A study of community-dwelling older adults in Japan. Geriatrics and Gerontology International. 17 (12), 2602- 2609 (2017)
[75] Sotaniemi, EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther. 61 (3), 331-339 (1997)
[76] Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metabolism Reviews. 41 (2), 67-76 (2009)
[77] Schmucker DL. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs and aging. 18 (11), 837-851 (2001)
[78] McLachlan AJ, Pont LG. Drug Metabolism in Older People - A Key Consideration in Achieving Optimal Outcomes With Medicines. J gerontol Ser A biol sci med sci. 67 A (2), 175-180 (2012)
[79] Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Bailliere's Best Practice and Research in Clinical Gastroenterology. 15 (6), 897-918 (2001)
[80] Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther. 23 (4), 247-255 (1998)
[81] Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet. 38 (3), 243-270 (2000)
[82] Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 44 (2), 275-283 (1992)
論文の公開元へ
